Is there utility in molecular or proteomic testing (e.g., Foundation or Caris) for metastatic clear cell renal cell carcinoma when several lines have failed?

The role of genomics is not well-defined in mRCC. In my personal experience there are very few truly actionable mutations that will be discovered. I would generally favor alternative FDA-approved agents of novl clinical trials.